Welcome to our dedicated page for Akero Therapeutics news (Ticker: AKRO), a resource for investors and traders seeking the latest updates and insights on Akero Therapeutics stock.
Akero Therapeutics (NASDAQ: AKRO) is a clinical-stage biotechnology company pioneering FGF21-based therapies for metabolic diseases including NASH and MASH. This page provides investors and researchers with timely updates on clinical developments, regulatory milestones, and corporate announcements directly from the company.
Access authoritative information on Akero's lead candidate efruxifermin (EFX), including Phase 2b/3 trial progress, peer-reviewed research, and strategic partnerships. Our curated news collection covers essential updates, scientific presentations, and financial reports while maintaining strict compliance with financial disclosure standards.
Key content includes trial result analyses, FDA communications, patent developments, and executive commentary. Bookmark this page for streamlined tracking of Akero's progress in addressing liver fibrosis and metabolic dysfunction through innovative Fc-FGF21 fusion protein therapy.
Akero Therapeutics (AKRO) has completed enrollment for its Phase 2b SYMMETRY study, assessing efruxifermin (EFX) in non-alcoholic steatohepatitis (NASH) patients with compensated cirrhosis (F4). Results for this study are expected in Q4 2023, while outcomes from the Cohort D expansion, evaluating EFX with GLP-1 therapy, are anticipated in Q2 2023. EFX, designated as a Breakthrough Therapy, aims to address urgent unmet needs in the NASH space, with a focus on fibrosis regression and improving metabolic parameters.
Akero Therapeutics announced that efruxifermin (EFX) has been granted Breakthrough Therapy Designation by the FDA for treating nonalcoholic steatohepatitis (NASH). This designation follows significant results from the Phase 2b HARMONY study, where both 50mg and 28mg doses of EFX met primary and secondary histology endpoints after 24 weeks. With an estimated 17 million Americans affected by NASH and no approved therapies available, this milestone could expedite the development of EFX as a potential treatment. Further trial results are expected in late 2023.
Akero Therapeutics (Nasdaq: AKRO) announced participation in two significant investor conferences this November. The company will engage in a fireside chat at the Jefferies London Healthcare Conference on November 17 at 8:00 a.m. GMT, and again at the EvercoreISI HealthCONx Conference on November 29 at 12:10 p.m. ET. Akero focuses on developing treatments for serious metabolic diseases like non-alcoholic steatohepatitis (NASH), with its lead candidate, efruxifermin (EFX), currently in two Phase 2b clinical trials.
Akero Therapeutics (Nasdaq: AKRO) is set to present significant findings from its Phase 2b HARMONY study on efruxifermin (EFX) for treating pre-cirrhotic NASH at the AASLD The Liver Meeting 2022. The oral presentation will detail Week 24 results, emphasizing EFX's potential as a foundational monotherapy for NASH. Additionally, a poster presentation will explore EFX’s unique molecular structure and its implications for pharmacological engagement. NASH affects 17 million Americans, with no approved treatments, highlighting the urgency for effective therapies.
Akero Therapeutics (Nasdaq: AKRO) reported its Q3 2022 financial results, highlighting promising Week 24 outcomes from the Phase 2b HARMONY study for EFX in pre-cirrhotic NASH. Key findings include 41% of patients on 50mg EFX showing fibrosis improvement, double the placebo rate. The company raised approximately $230 million in a recent public offering and believes its cash reserves will support operations until 2025. Operating expenses rose to $36.1 million, up from $24.4 million in Q3 2021, primarily due to increased R&D costs.
Akero Therapeutics (Nasdaq: AKRO) announced its participation in the H.C. Wainwright 6th Annual NASH Virtual Investor Conference on October 17, 2022, at 12:00 p.m. E.T. The webcast will be accessible via the company's investor relations website, with an archived replay available afterward.
Akero is focused on developing innovative treatments for serious metabolic diseases, particularly non-alcoholic steatohepatitis (NASH), which currently has no approved therapies. Their lead candidate, efruxifermin (EFX), shows promise as a potential best-in-class option for NASH treatment.
Akero Therapeutics (AKRO) has successfully closed its upsized public offering, issuing 8,846,154 shares at $26.00 each, raising approximately $230 million in gross proceeds. This offering included the full exercise of an underwriters' option for an additional 1,153,846 shares. J.P. Morgan, Morgan Stanley, and Jefferies managed the offering with Canaccord Genuity as a lead manager. The company is focused on developing treatments for serious metabolic diseases, notably NASH, with its lead candidate, efruxifermin (EFX), currently in two Phase 2b trials.
Akero Therapeutics (Nasdaq: AKRO) has announced an upsized public offering of 7,692,308 shares at a price of $26.00 per share, aiming to raise approximately $200 million. The underwriters have a 30-day option to purchase an additional 1,153,846 shares. The offering is set to close on or around September 19, 2022, subject to customary conditions. J.P. Morgan, Morgan Stanley, and Jefferies serve as joint book-running managers. Proceeds are intended to advance Akero's clinical development pipeline, particularly for its lead product candidate, efruxifermin, targeting serious metabolic diseases.
Akero Therapeutics (Nasdaq: AKRO) has announced an underwritten public offering of $175 million in shares of its common stock, with an option for underwriters to purchase an additional $26.25 million. This offering is part of the company's strategy to develop treatments for serious metabolic diseases, including non-alcoholic steatohepatitis (NASH). The offering is subject to market conditions and involves major underwriters including J.P. Morgan and Morgan Stanley. An effective shelf registration statement has been filed with the SEC for this purpose.
Akero Therapeutics (Nasdaq: AKRO) announces significant topline results from its Phase 2b HARMONY study of efruxifermin (EFX) for nonalcoholic steatohepatitis (NASH) treatment.
Patients receiving 50mg and 28mg doses showed notable improvements: 41% and 39% had fibrosis improvement, and 76% and 47% achieved NASH resolution, far surpassing placebo rates. Additionally, EFX led to better liver fat, enzyme control, and weight management.
Results signal strong potential for EFX in addressing NASH, a major health crisis, with detailed discussions in an investor webcast.
FAQ
What is the current stock price of Akero Therapeutics (AKRO)?
What is the market cap of Akero Therapeutics (AKRO)?
